>>15626302 (pb)
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy
Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development